Table 1 Target antigen combinations in commercially available RDTs. Adapted from [34].
From: Working without a blindfold: the critical role of diagnostics in malaria control
RDT type | Target antigens | Possible results |
|---|---|---|
I | HRP2 | No Pf |
| Â | Â | Pf |
| Â | Â | Invalid |
II | HRP2 | No malaria |
| Â | Aldolase (all species) | Pf or mixed |
| Â | Â | Pv, Po, and/or Pm |
| Â | Â | Invalid |
III | HRP2 | No malaria |
| Â | pLDH (all species) | Pf or mixed |
| Â | Â | Pv, Po, and/or Pm |
| Â | Â | Invalid |
IV | pLDH (falciparum-specific) | No malaria |
| Â | pLDH (all species) | Pf or mixed |
| Â | Â | Invalid |
V | pLDH (falciparum-specific) | No malaria |
| Â | pLDH (vivax-specific) | Pf |
| Â | Â | Pv |
| Â | Â | Pf + Pv |
| Â | Â | Invalid |
VI | HRP2 | No malaria |
| Â | pLDH (falciparum-specific) | Pf or mixed |
| Â | pLDH (vivax-specific) | Pf + Pv, +/- Po and/or Pm |
| Â | Â | Pf +/- Po and/or Pm |
| Â | Â | Pv +/- Po and/or Pm |
| Â | Â | Po and/or Pm |
| Â | Â | Invalid |
VII | Aldolase (all species) | No malaria |
| Â | Â | Pf, Pv, Po and/or Pm |
| Â | Â | Invalid |